

# World Journal of *Clinical Cases*

*World J Clin Cases* 2020 December 6; 8(23): 5835-6212



**EDITORIAL**

- 5835 Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy  
*Shimizu Y*

**OPINION REVIEW**

- 5844 What is the gut feeling telling us about physical activity in colorectal carcinogenesis?  
*Cigrovski Berkovic M, Cigrovski V, Bilic-Curcic I, Mrzljak A*

**REVIEW**

- 5852 Latest developments in chronic intestinal pseudo-obstruction  
*Zhu CZ, Zhao HW, Lin HW, Wang F, Li YX*

**ORIGINAL ARTICLE****Case Control Study**

- 5866 Correlation between ductus venosus spectrum and right ventricular diastolic function in isolated single-umbilical-artery foetus and normal foetus in third trimester  
*Li TG, Nie F, Xu XY*

**Retrospective Cohort Study**

- 5876 Clinical efficacy of integral theory-guided laparoscopic integral pelvic floor/ligament repair in the treatment of internal rectal prolapse in females  
*Yang Y, Cao YL, Zhang YY, Shi SS, Yang WW, Zhao N, Lyu BB, Zhang WL, Wei D*

**Retrospective Study**

- 5887 Treatment of Kümmell's disease with sequential infusion of bone cement: A retrospective study  
*Zhang X, Li YC, Liu HP, Zhou B, Yang HL*
- 5894 Application value analysis of magnetic resonance imaging and computed tomography in the diagnosis of intracranial infection after craniocerebral surgery  
*Gu L, Yang XL, Yin HK, Lu ZH, Geng CJ*
- 5902 Focal intrahepatic strictures: A proposal classification based on diagnosis-treatment experience and systemic review  
*Zhou D, Zhang B, Zhang XY, Guan WB, Wang JD, Ma F*
- 5918 Preliminary analysis of the effect of vagus nerve stimulation in the treatment of children with intractable epilepsy  
*Fang T, Xie ZH, Liu TH, Deng J, Chen S, Chen F, Zheng LL*

- 5926** Scoring system for poor limb perfusion after limb fracture in children  
*Zhu T, Shi Y, Yu Q, Zhao YJ, Dai W, Chen Y, Zhang SS*
- 5935** Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment  
*Wang RB, Li YC, Zhou Q, Lv SZ, Yuan KY, Wu JP, Zhao YJ, Song QK, Zhu B*
- 5944** Application of computer tomography-based 3D reconstruction technique in hernia repair surgery  
*Wang F, Yang XF*
- 5952** Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases  
*Zhu HM, Li Y, Li BY, Yang S, Peng D, Yang X, Sun XL, Zhang M*
- Observational Study**
- 5962** Genetic diagnosis history and osteoarticular phenotype of a non-transfusion secondary hemochromatosis  
*Ruan DD, Gan YM, Lu T, Yang X, Zhu YB, Yu QH, Liao LS, Lin N, Qian X, Luo JW, Tang FQ*
- 5976** Abdominal ventral rectopexy with colectomy for obstructed defecation syndrome: An alternative option for selected patients  
*Wang L, Li CX, Tian Y, Ye JW, Li F, Tong WD*
- 5988** Surgical treatment of multiple magnet ingestion in children: A single-center study  
*Cai DT, Shu Q, Zhang SH, Liu J, Gao ZG*

**CASE REPORT**

- 6009** Duodenal giant stromal tumor combined with ectopic varicose hemorrhage: A case report  
*Li DH, Liu XY, Xu LB*
- 6016** Healthy neonate born to a SARS-CoV-2 infected woman: A case report and review of literature  
*Wang RY, Zheng KQ, Xu BZ, Zhang W, Si JG, Xu CY, Chen H, Xu ZY, Wu XM*
- 6026** Pleomorphic adenoma of the trachea: A case report and review of the literature  
*Liao QN, Fang ZK, Chen SB, Fan HZ, Chen LC, Wu XP, He X, Yu HP*
- 6043** Huge encrusted ureteral stent forgotten for over 25 years: A case report  
*Kim DS, Lee SH*
- 6048** Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report  
*Yu WH, Li XJ, Yuan F*
- 6056** Suspected SARS-CoV-2 infection with fever and coronary heart disease: A case report  
*Gong JR, Yang JS, He YW, Yu KH, Liu J, Sun RL*
- 6064** Interpersonal psychotherapy-based psychological intervention for patient suffering from COVID-19: A case report  
*Hu CC, Huang JW, Wei N, Hu SH, Hu JB, Li SG, Lai JB, Huang ML, Wang DD, Chen JK, Zhou XY, Wang Z, Xu Y*

- 6071** Optical coherence tomography angiography characteristics in Waldenström macroglobulinemia retinopathy: A case report  
*Li J, Zhang R, Gu F, Liu ZL, Sun P*
- 6080** Forty-nine years old woman co-infected with SARS-COV-2 and Mycoplasma: A case report  
*Gao ZA, Gao LB, Chen XJ, Xu Y*
- 6086** Endoscopic fenestration in the diagnosis and treatment of delayed anastomotic submucosal abscess: A case report and review of literature  
*Zhang BZ, Wang YD, Liao Y, Zhang JJ, Wu YF, Sun XL, Sun SY, Guo JT*
- 6095** Small-cell neuroendocrine carcinoma of the rectum – a rare tumor type with poor prognosis: A case report and review of literature  
*Chen ZZ, Huang W, Wei ZQ*
- 6103** Laparoscopic left lateral sectionectomy in pediatric living donor liver transplantation by single-port approach: A case report  
*Li H, Wei L, Zeng Z, Qu W, Zhu ZJ*
- 6110** Malignant meningioma with jugular vein invasion and carotid artery extension: A case report and review of the literature  
*Chen HY, Zhao F, Qin JY, Lin HM, Su JP*
- 6122** Neuronal intranuclear inclusion disease mimicking acute cerebellitis: A case report  
*Guo JJ, Wang ZY, Wang M, Jiang ZZ, Yu XF*
- 6130** Hemophagocytic lymphohistiocytosis caused by STAT1 gain-of-function mutation is not driven by interferon- $\gamma$ : A case report  
*Liu N, Zhao FY, Xu XJ*
- 6136** Single door laminoplasty plus posterior fusion for posterior atlantoaxial dislocation with congenital malformation: A case report and review of literature  
*Zhu Y, Wu XX, Jiang AQ, Li XF, Yang HL, Jiang WM*
- 6144** Occipital nodular fasciitis easily misdiagnosed as neoplastic lesions: A rare case report  
*Wang T, Tang GC, Yang H, Fan JK*
- 6150** Postoperative secondary aggravation of obstructive sleep apnea-hypopnea syndrome and hypoxemia with bilateral carotid body tumor: A case report  
*Yang X, He XG, Jiang DH, Feng C, Nie R*
- 6158** Uncontrolled central hyperthermia by standard dose of bromocriptine: A case report  
*Ge X, Luan X*
- 6164** Acute celiac artery occlusion secondary to blunt trauma: Two case reports  
*Li H, Zhao Y, Xu YA, Li T, Yang J, Hu P, Ai T*

- 6172** Multiple ectopic goiter in the retroperitoneum, abdominal wall, liver, and diaphragm: A case report and review of literature  
*Qin LH, He FY, Liao JY*
- 6181** Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review  
*Pang QL, He WC, Li JX, Huang L*
- 6190** Primary breast cancer patient with poliomyelitis: A case report  
*Wang XM, Cong YZ, Qiao GD, Zhang S, Wang LJ*
- 6197** Discontinuous polyostotic fibrous dysplasia with multiple systemic disorders and unique genetic mutations: A case report  
*Lin T, Li XY, Zou CY, Liu WW, Lin JF, Zhang XX, Zhao SQ, Xie XB, Huang G, Yin JQ, Shen JN*
- 6206** Novel triple therapy for hemorrhagic ascites caused by endometriosis: A case report  
*Han X, Zhang ST*

**ABOUT COVER**

Peer-reviewer of *World Journal of Clinical Cases*, Dr. Mohamad Adam Bujang is a Research Officer at the Institute for Clinical Research, Ministry of Health, Malaysia. After receiving his Bachelor's degree in Statistics from MARA University of Technology in 2004, Dr. Adam undertook his postgraduate study at the same university, receiving his Master's degree (MBA) in 2008 and his PhD in Information Technology and Quantitative Sciences in 2017. Currently, he works as a biostatistician and researcher in the Clinical Research Centre, Sarawak General Hospital. His ongoing research interests involve such research methodologies as sampling techniques, sample size planning, and statistical analyses. Since 2016, he has served as an active member of the Malaysia Institute of Statistics and the Association of Clinical Registries Malaysia. (L-Editor: Filipodia)

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

*WJCC* mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The *WJCC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJCC* as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yan-Xia Xing; Production Department Director: Yun-Xiaojian Wu; Editorial Office Director: Jin-Lai Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Semimonthly

**EDITORS-IN-CHIEF**

Dennis A Bloomfield, Sandro Vento, Bao-gan Peng

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

December 6, 2020

**COPYRIGHT**

© 2020 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy

Yukihiro Shimizu

**ORCID number:** Yukihiro Shimizu  
0000-0002-8216-9269.

**Author contributions:** Yukihiro Shimizu alone designed and wrote the paper.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report's scientific quality classification**  
Grade A (Excellent): 0

**Yukihiro Shimizu**, Gastroenterology Center, Nanto Municipal Hospital, Nanto 932-0211, Toyama, Japan

**Corresponding author:** Yukihiro Shimizu, MD, PhD, Director, Doctor, Gastroenterology Center, Nanto Municipal Hospital, 938 Inami, Nanto 932-0211, Toyama, Japan. [rsf14240@nifty.com](mailto:rsf14240@nifty.com)

### Abstract

Although 80% of individuals infected with the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) recover without antiviral treatments, the other 20% progress to severe forms of pulmonary disease, suggesting that the host's immune response to the virus could influence the outcome of coronavirus disease 2019 (COVID-19). SARS-CoV-2 infects alveolar epithelial type 2 cells expressing angiotensin-converting enzyme 2, and these infected epithelial cells recruit dendritic cells, neutrophils and monocytes/macrophages, leading to the activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells. These cells launch an antiviral immune response, but are able to completely suppress viral replication or completely eradicate virus in a limited proportion of infected patients. In other patients, viral suppression is incomplete and the numbers of circulating B and T cells are subsequently reduced by as yet unknown mechanisms. Some patients with sustained viral replication progress to a severe condition called cytokine storm. Although antiviral drug(s) should be considered early in infection to prevent progression, there have been no antiviral therapies proven to be effective for significantly inhibiting the viral replication *in vivo* and suppressing the progression to cytokine storm. Blocking the action of cytokines with dexamethasone or anti-interleukin-6 could have a pivotal role in treatment of those patients. Therapeutic strategy should therefore be based on viral kinetics and the immunopathology of COVID-19.

**Key Words:** COVID-19; SARS-CoV-2; Immune response; Antibody; Viral kinetics; Treatment

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Since the coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the core therapeutic strategy

Grade B (Very good): B  
 Grade C (Good): C  
 Grade D (Fair): 0  
 Grade E (Poor): 0

**Received:** May 15, 2020

**Peer-review started:** May 15, 2020

**First decision:** November 3, 2020

**Revised:** November 12, 2020

**Accepted:** November 21, 2020

**Article in press:** November 21, 2020

**Published online:** December 6, 2020

**P-Reviewer:** Zhuo ZQ

**S-Editor:** Chen XF

**L-Editor:** A

**P-Editor:** Ma YJ



should be aimed at the eradication of the virus. Unfortunately, there have been no antiviral drugs proven to be effective for this viral infection. The pathogenesis of SARS-CoV-2 is formed by the interaction between the viral infection and the immune response to the virus, and the various clinical features observed in patients with COVID-19 could be due to differences in host immune responses. Moreover, therapeutic strategies should be based on both viral kinetics and the immune response. This editorial summarizes current understanding about immune responses in patients infected with SARS-CoV-2 and provides clues to therapeutic strategies based on this information.

**Citation:** Shimizu Y. Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. *World J Clin Cases* 2020; 8(23): 5835-5843

**URL:** <https://www.wjgnet.com/2307-8960/full/v8/i23/5835.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v8.i23.5835>

## INTRODUCTION

A novel coronavirus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), which emerged in 2019 in Wuhan, China, has been found to cause acute respiratory syndrome called coronavirus disease 2019 (COVID-19), with some patients developing a severe form of this disease leading to death. This virus is the third highly pathogenic coronavirus reported to date and has caused a worldwide outbreak of infection called a pandemic. Around 80% of individuals infected with SARS-CoV-2 appear to recover without antiviral treatments<sup>[1]</sup>, indicating that an adequate host immune response against the virus may be sufficient to cure the viral infection. In contrast, the other 20% of patients develop severe forms of this disease, suggesting that an inadequate immune response may predispose to poorer outcomes. Understanding host immune responses against SARS-CoV-2 may be important in designing therapeutic strategies to fight viral infection.

## UNDERSTANDING THE IMMUNOPATHOGENESIS OF COVID-19

### ***Virology of SARS-CoV-2***

Coronaviruses are enveloped viruses with a single-stranded positive sense RNA. For the virus to enter host cells, the spike (S) protein on the surface of SARS-CoV-2, after priming by the host serine protease TMPRSS2, binds to the host cell angiotensin-converting enzyme 2 (ACE2) receptor<sup>[2]</sup>. The structure of the receptor-binding domain (RBD) of S protein that binds to the ACE2 receptor has been determined<sup>[3]</sup>, and antibody (Ab) against this RBD is thought to have the ability to neutralize the virus. Cells abundantly expressing ACE2 include alveolar type 2 cells of the lungs and gastrointestinal epithelial cells<sup>[4]</sup>, but any cells expressing ACE2 could be targeted by the virus. Whether SARS-CoV-2 has cytopathic effects (CPE) is unknown, but Middle East respiratory syndrome coronavirus has been reported to induce apoptosis of lung cells through upregulation of Smad7 and fibroblast growth factor 2 expression<sup>[5]</sup>. Therefore, high replication of SARS-CoV-2 may also induce CPE, which could be involved in the pathogenesis of viral infection. In contrast, alveolar type 2 cells infected with SARS-CoV-2 or alveolar macrophages have been reported to produce cytokines and chemokines. Although these molecules may activate immune responses against the virus, they could also contribute to the pathogenesis of lung diseases and thrombosis<sup>[6]</sup>. The cellular mechanism underlying the pathogenesis induced by SARS-CoV-2 infection is thus thought to be complex, involving viral replication and immune responses against infected cells.

### ***Immune response to SARS-CoV-2***

**Innate immunity:** Following viral infection, the innate immune system is immediately activated to eliminate pathogens without harming host cells. This system is responsible for host defenses until the development of acquired immunity, with T and B cell responses being fully activated 7 or more days after infection<sup>[7]</sup>. Cells involved in

innate immunity include dendritic cells, macrophages, neutrophils and natural killer (NK) cells. Although little is known about innate immune responses to SARS-CoV-2 infection, the expression of type I interferon (IFN), which is usually produced by virus-infected cells and can suppress viral replication and limit the dissemination of infected cells, is thought to be suppressed in COVID-19<sup>[9]</sup>. However, an analysis of temporal dynamics in viral shedding showed that the peak of viral shedding from the throat occurs prior to the onset of symptoms and gradually decreases thereafter<sup>[9]</sup>, suggesting that an antiviral innate immune response suppresses viral replication during early phases of COVID-19. The innate immune response, coupled with subsequent acquired immune responses, may be sufficient to eradicate the virus in 80% of infected patients, who recover without antiviral treatments, but may not be vigorous enough to eradicate the virus in the remaining infected patients. Sustained replication of the virus in the latter patients may trigger subsequent inflammatory responses and recruit excess numbers of dendritic cells, T cells, B cells, NK cells, neutrophils and monocytes/macrophages<sup>[10]</sup>, leading to the development of moderate and severe pathology of the lungs. Cells are thought to be recruited by cytokines, such as tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-6, and chemokines, such as CCL2/MCP-1, CCL3/MIP-1 $\alpha$ , and CXCL10/IP-10, which are produced by infected airway epithelial cells and alveolar macrophages, as reported in a mouse model of SARS-CoV infection<sup>[6]</sup>.

**SARS-CoV-2 specific B cell responses:** B cell populations were shown to be lower in patients with severe COVID-19 than in control individuals<sup>[11]</sup>. The role of B cells in the pathogenesis of COVID-19 remains unclear, but a report of SARS-CoV-2 infection in patients with B cell defects may provide important information on their role. SARS-CoV-2 infection of patients with agammaglobulinemia lacking B cells resulted in a short course of infection with mild severity<sup>[12]</sup>. Although evidence in additional patients is needed to determine the role of B cells in the pathogenesis of COVID-19, these findings suggest that B cells may not be required to control infection.

Abs against the RBD of the S protein of SARS-CoV-2 have been observed frequently in infected patients, with seroconversion rates of putative neutralizing total, IgM, and IgG antibodies being 93.1%, 87.2% and 64.7%, respectively, and their median seroconversion times being 11 d, 12 d and 14 d, respectively<sup>[13]</sup>. These findings suggest that B cell function is preserved, despite reductions in the numbers of circulating B cells. An analysis of the temporal profile of serum Abs found that rates of seropositivity for anti-nucleocapsid protein IgG and IgM Abs were 94% and 88%, respectively, while the rates of seropositivity for anti-RBD IgG and IgM Abs were 100% and 94%, respectively<sup>[14]</sup>. Ab responses were found to be faster and higher in severe than in mild cases. Although IgM responses generally precede IgG responses, both were found to occur almost simultaneously in subjects infected with SARS-CoV-2<sup>[14]</sup>. Therefore, measuring both IgM and IgG Abs would have high sensitivity for the diagnosis of acute infection. However, the absence of Abs does not preclude recent infection, as not all patients develop Ab responses and the levels of neutralizing Abs detected after infection were found to be decreased or disappear in the early convalescent phase<sup>[15]</sup>.

Because neutralizing IgG Abs are present in the blood of many patients who recover from acute SARS-CoV-2 infection<sup>[16]</sup>, the plasma from convalescing patients has been utilized to treat those actively infected with SARS-CoV-2<sup>[17-19]</sup>. Infusion of convalescent plasma was found to be effective, even in critically ill patients with acute respiratory distress syndrome (ARDS)<sup>[19]</sup>. Because cytokine storm is the main pathogenic mechanism involved in the development of ARDS, the effect observed by infusion of convalescent plasma may be due not only to neutralizing Abs but to putative immunoregulatory molecules that can inhibit cytokine overproduction.

It is unclear, however, whether patients who recover from COVID-19 are protected from the effects of re-exposure to the virus. The World Health Organization stated that there is currently no evidence showing that recovered patients are protected from a second infection<sup>[20]</sup>. However, a model of SARS-CoV-2 infection in rhesus macaques demonstrated that primary infection with SARS-CoV-2 induced successful protection from re-infection<sup>[21]</sup>. Additional studies are required to determine whether protective immunity against SARS-CoV-2 develops after primary infection, because these data are important in determining whether vaccines against SARS-CoV-2 would be effective in preventing re-infection.

**SARS-CoV-2 and T cell responses:** Both CD4+ and CD8+ T cells are actively involved in the pathogenesis of COVID-19<sup>[22]</sup>, and the percentages, but not the absolute numbers, of circulating CD4+ and CD8+ T cells producing IFN- $\gamma$  were found to be

higher in severely infected than in mildly infected patients<sup>[11]</sup>. Moreover, S protein-specific CD4+ T cells have been detected in infected patients<sup>[23]</sup>. These CD4+ T cells may be cross-reactive clones against SARS-CoV-2, which may have developed in response to endemic coronavirus infection, because these T cells have been detected in some uninfected persons<sup>[23]</sup>.

Many studies have indicated that both CD4+ and CD8+ T cell populations are decreased in response to SARS-CoV-2 infection, especially in severe cases, indicating that overall T cell response becomes impaired during the progression of the disease<sup>[22,24]</sup>. The mechanism responsible for T cell decrease in COVID-19 is unclear, but T cell apoptosis may result from the defective activation of T cells by virus-infected dendritic cells<sup>[25]</sup>.

Virus-specific memory CD8+ T cells were shown to protect infected individuals from the lethality of COVID-19<sup>[26]</sup>. Therefore, a decreased CD8+ T cell response in COVID-19 patients may lead to inadequate control of viral replication. Moreover, the increased expression of NKG2A in CD8+ T cells and NK cells of patients with COVID-19 indicated that these cells may have been exhausted, possibly from the high viral load in inflamed tissues<sup>[27]</sup>. These findings suggest an inadequate antiviral CD8+ T cell response to SARS-CoV-2 infection is associated with progression to the severe form of the disease.

CD4+ T cells also play an important role in controlling viral replication<sup>[16]</sup>. Both the numbers and functions of CD4+ T cells were found to be reduced in patients with COVID-19<sup>[22]</sup>. However, the role of CD4+ T cells in the control of SARS-CoV-2 infection is unclear, because the course of disease was mild in patients co-infected with SARS-CoV-2 and human immunodeficiency virus (HIV) and having low CD4+ T cell counts, similar to findings in immunocompetent persons<sup>[28-30]</sup>. The immunosuppressive state with low CD4+ T cell counts observed in HIV-infected patients may enable their escape from harmful immune over-responses. Similarly, a mild course of infection was observed in SARS-CoV-2-infected patients with chronic arthritis who were being treated with immunosuppressive agents<sup>[31]</sup>. Moreover, a mouse model of SARS-CoV infection showed that viral clearance could occur even after the depletion of both CD4+ and CD8+ T cells, with viral clearance resulting from the accumulation of dendritic cells and neutrophils, recruited by MCP-1/CCL2 and MIP-2 $\beta$ /CXCL2<sup>[32]</sup>. Collectively, although the numbers and functions of both CD4+ T cells and CD8+ T cells are decreased in COVID-19 patients, additional investigations are required to determine the precise mechanisms underlying these reductions and the roles of both T cell subsets in the control and pathogenesis of COVID-19.

**Cytokine storm:** Of 138 patients hospitalized for SARS-CoV-2-infected pneumonia, 36 (26.1%) were transferred to the intensive care unit during the clinical course of the disease because of complications, including ARDS, arrhythmia, and shock<sup>[33]</sup>. The disease rapidly progressed in these patients, with a median time from first symptom to ARDS being 8.0 d<sup>[33]</sup>. Because most deaths of SARS-CoV-2-infected patients are caused by its complications, especially ARDS<sup>[34]</sup>, understanding the mechanism by which these infected patients develop ARDS is important for their management and can reduce mortality rates. Although relatively little is known about the factors associated with progression to severe disease, the main pathophysiology of ARDS was shown to be cytokine release syndrome (CRS)<sup>[25]</sup>, also called cytokine storm. Cytokines and chemokines overproduced in a cytokine storm include IL-1 $\beta$ , IL-2, IL-6, IL-10, TNF- $\alpha$ , IFN- $\gamma$ , IP-10, MIP-1, and MIP-1 $\alpha$ <sup>[35]</sup>. IL-6 is thought to be a key factor, because serum IL-6 concentration was associated with disease severity<sup>[36]</sup> and mortality<sup>[37]</sup>. IL-6 is synthesized by macrophages and dendritic cells upon recognition of pathogens through toll-like receptors at the site of infection<sup>[38]</sup>. Circulating IL-6 binds to the soluble form of IL-6 receptor, forming a complex with a gp130 dimer on potentially all cell surfaces. The complex activates the JAK-STAT3 signaling pathway in various cell types, including endothelial cells, resulting in CRS and finally leading to ARDS<sup>[38]</sup>. Blocking this pathway could have therapeutic effects against CRS and ARDS in patients with a severe form of COVID-19.

---

## FROM UNDERSTANDING OF IMMUNE RESPONSE TO THERAPEUTIC STRATEGY

---

The pathogenesis of SARS-CoV-2 is formed by the interaction between the viral infection and the immune response to the virus as mentioned so far. Therefore,

understanding the immune response in the viral infection is important to manage the viral infection.

Immune responses to SARS-CoV-2 infection can be summarized as follows: After infection with SARS-CoV-2, the virus enters ACE2-expressing alveolar epithelial type 2 cells. These infected epithelial cells recruit dendritic cells, neutrophils and monocytes/macrophages, leading to the activation of CD4+ and CD8+ T cells. These cells exert anti-viral immune responses, completely suppressing viral replication or eradicating the virus in almost 80% of infected patients. In the remaining 20%, however, T cell populations are reduced due to unclear mechanisms. Rather, a cytokine storm occurs, resulting in various complications such as ARDS. Various cytokines including IL-6, produced by activated dendritic cells and monocytes/macrophages, are thought to be key factors causing the severe pulmonary disease (Figure 1).

Because COVID-19 is caused by SARS-CoV-2, the core therapeutic strategy should be aimed at the eradication of the virus<sup>[39]</sup>. Antiviral drugs clinically used so far include remdesivir<sup>[40]</sup>, favipiravir<sup>[41]</sup>, chloroquine<sup>[42]</sup>, hydroxychloroquine<sup>[43]</sup>, and lopinavir/ritonavir<sup>[44]</sup>. Remdesivir and favipiravir are RNA-dependent RNA polymerase inhibitors shown to inhibit viral replication *in vitro*. The United States Food and Drug Administration has allowed the "Emergency Use" of remdesivir as an experimental drug in the United States. However, there have been no antiviral drugs proven to be virally effective for this viral infection.

Theoretically, effective antiviral drugs should be administered during an early phase of the disease, after the onset of symptoms, when viral replication seems still active based on temporal changes in viral load<sup>[14]</sup> and immune response<sup>[22]</sup>. However, immediate use of antivirals after the onset of symptoms is questionable, because antiviral drugs administered under conditions of high viral replication can predispose to the emergence of drug-resistant mutants. Moreover, not all patients require antiviral drugs as 80% of patients have shown spontaneous eradication of the virus in the absence of antiviral drugs<sup>[1]</sup>. Therefore, candidates for treatment with antiviral drugs include patients in the acute phase of the disease with mild to moderate severity, and those with persistent symptoms lasting for several days without improvements or showing indications of progression to the severe form of the disease.

The mortality rate in patients who progress to the severe form of the disease is 50%<sup>[34]</sup>. Antiviral drugs do not play a pivotal role in those patients because viral replication is not the main pathogenesis at the time of cytokine storm. Rather, these patients may benefit from immunomodulatory treatment. Drugs that block IL-6 activity may be effective. For example, treatment with tocilizumab, a monoclonal antibody that binds the soluble form of IL-6 receptor, markedly improved the respiratory condition and resolved computed tomography findings of the lungs in 80% of severely ill COVID-19 patients<sup>[45]</sup>. Recently, dexamethasone has been shown to reduce the progression of severe lung injury and mortality of the patients<sup>[46,47]</sup>. Although those data are promising, immunosuppression by those agents may delay viral clearance<sup>[23]</sup>, suggesting that co-administration of an effective antiviral drug may be beneficial.


Other therapeutic options for cytokine storm include convalescent plasma<sup>[8-10]</sup> and the plasma has shown promise in the treatment of the severe form of COVID-19<sup>[16-18]</sup>. However, because plasma may contain unknown viruses transmittable to the recipient, this treatment should be considered only if no other treatments result in patient improvement.

---

## CONCLUSION

---

In conclusion, the treatment strategy for patients with COVID-19 should be carefully designed based on both viral kinetics and immunopathogenesis. However, pandemic infection with SARS-CoV-2 may persist for several months, even if treatments are effective. The development of an effective vaccine will be necessary for termination of this pandemic infection.



**Figure 1** Therapeutic strategy based on viral kinetics and immunopathogenesis during the course of coronavirus disease 2019. sIL-6 receptor: Soluble form of interleukin-6 receptor; NK cells: Natural killer cells; TNF- $\alpha$ : Tumor necrosis factor-alpha.

## REFERENCES

- 1 **Wu Z**, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239-1242 [PMID: [32091533](#) DOI: [10.1001/jama.2020.2648](#)]
- 2 **Hoffmann M**, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**: 271-280 [PMID: [32142651](#) DOI: [10.1016/j.cell.2020.02.052](#)]
- 3 **Lan J**, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020; **581**: 215-220 [PMID: [32225176](#) DOI: [10.1038/s41586-020-2180-5](#)]
- 4 **Coma A**, Jonte F, Zanabali Y, Soto I, Fanjul F, Carrera D, Rayón C, Luño E, Jalón S, Pinto V. [Low-grade non-Hodgkin's lymphomas. Study of 73 cases]. *Sangre (Barc)* 1992; **37**: 215-220 [PMID: [1514137](#)]
- 5 **Yeung ML**, Yao Y, Jia L, Chan JF, Chan KH, Cheung KF, Chen H, Poon VK, Tsang AK, To KK, Yiu MK, Teng JL, Chu H, Zhou J, Zhang Q, Deng W, Lau SK, Lau JY, Woo PC, Chan TM, Yung S, Zheng BJ, Jin DY, Mathieson PW, Qin C, Yuen KY. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. *Nat Microbiol* 2016; **1**: 16004 [PMID: [27572168](#) DOI: [10.1038/nmicrobiol.2016.4](#)]
- 6 **Morris G**, Bortolasci CC, Puri BK, Olive L, Marx W, O'Neil A, Athan E, Carvalho AF, Maes M, Walder K, Berk M. The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. *Life Sci* 2020; **258**: 118166 [PMID: [32739471](#) DOI: [10.1016/j.lfs.2020.118166](#)]
- 7 **Akira S**, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006; **124**: 783-801 [PMID: [16497588](#) DOI: [10.1016/j.cell.2006.02.015](#)]
- 8 **Rokni M**, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. *Rev Med Virol* 2020; **30**: e2107 [PMID: [32267987](#) DOI: [10.1002/rmv.2107](#)]
- 9 **Kang S**, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. *Immunity*

- 2019; **50**: 1007-1023 [PMID: 30995492 DOI: 10.1016/j.immuni.2019.03.026]
- 10 **Promptchara E**, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pac J Allergy Immunol* 2020; **38**: 1-9 [PMID: 32105090 DOI: 10.12932/AP-200220-0772]
  - 11 **Wang F**, Hou H, Luo Y, Tang G, Wu S, Huang M, Liu W, Zhu Y, Lin Q, Mao L, Fang M, Zhang H, Sun Z. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. *JCI Insight* 2020; **5**: e137799 [PMID: 32324595 DOI: 10.1172/jci.insight.137799]
  - 12 **Quinti I**, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, Mastroianni CM, Turriziani O, Bondioni MP, Filippini M, Soresina A, Spadaro G, Agostini C, Carsetti R, Plebani A. A possible role for B cells in COVID-19? *J Allergy Clin Immunol* 2020; **146**: 211-213 [PMID: 32333914 DOI: 10.1016/j.jaci.2020.04.013]
  - 13 **Zhao J**, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* 2020 [PMID: 32221519 DOI: 10.1093/cid/ciaa344]
  - 14 **To KK**, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020; **20**: 565-574 [PMID: 32213337 DOI: 10.1016/S1473-3099(20)30196-1]
  - 15 **Long QX**, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020; **26**: 1200-1204 [PMID: 32555424 DOI: 10.1038/s41591-020-0965-6]
  - 16 **Zhang L**, Pang R, Xue X, Bao J, Ye S, Dai Y, Zheng Y, Fu Q, Hu Z, Yi Y. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. *Aging* 2020; **12**: 6536-6542 [PMID: 32320384 DOI: 10.18632/aging.103102]
  - 17 **Ye M**, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol* 2020; **92**: 1890-1901 [PMID: 32293713 DOI: 10.1002/jmv.25882]
  - 18 **Bloch EM**, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest* 2020; **130**: 2757-2765 [PMID: 32254064 DOI: 10.1172/JCI138745]
  - 19 **Shen C**, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* 2020; **323**: 1582-1589 [PMID: 32219428 DOI: 10.1001/jama.2020.4783]
  - 20 **WHO**. "Immunity passports" in the context of COVID-19. 2020. Available from: <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>
  - 21 **Deng W**, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* 2020; **369**: 818-823 [PMID: 32616673 DOI: 10.1126/science.abc5343]
  - 22 **Chen G**, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; **130**: 2620-2629 [PMID: 32217835 DOI: 10.1172/JCI137244]
  - 23 **Pia L**. SARS-CoV-2-reactive T cells in patients and healthy donors. *Nat Rev Immunol* 2020; **20**: 353 [PMID: 32355329 DOI: 10.1038/s41577-020-0333-2]
  - 24 **Bender AE**. Food additives. *Sci Prog* 1988; **72**: 549-562 [PMID: 3232067 DOI: 10.1016/j.chom.2020.04.009]
  - 25 **Moore JB**, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020; **368**: 473-474 [PMID: 32303591 DOI: 10.1126/science.abb8925]
  - 26 **Channappanavar R**, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. *J Virol* 2014; **88**: 11034-11044 [PMID: 25056892 DOI: 10.1128/JVI.01505-14]
  - 27 **Zheng M**, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol* 2020; **17**: 533-535 [PMID: 32203188 DOI: 10.1038/s41423-020-0402-2]
  - 28 **Blanco JL**, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, Miro JM; COVID-19 in HIV Investigators. COVID-19 in patients with HIV: clinical case series. *Lancet HIV* 2020; **7**: e314-e316

- [PMID: 32304642 DOI: 10.1016/S2352-3018(20)30111-9]
- 29 **Mascolo S**, Romanelli A, Carleo MA, Esposito V. Could HIV infection alter the clinical course of SARS-CoV-2 infection? *J Med Virol* 2020; **92**: 1777-1778 [PMID: 32293709 DOI: 10.1002/jmv.25881]
  - 30 **Wang M**, Luo L, Bu H, Xia H. One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4<sup>+</sup> T-cell count. *Int J Infect Dis* 2020; **96**: 148-150 [PMID: 32335339 DOI: 10.1016/j.ijid.2020.04.060]
  - 31 **Monti S**, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis* 2020; **79**: 667-668 [PMID: 32241793 DOI: 10.1136/annrheumdis-2020-217424]
  - 32 **Chen J**, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4<sup>+</sup> T cells are important in control of SARS-CoV infection. *J Virol* 2010; **84**: 1289-1301 [PMID: 19906920 DOI: 10.1128/JVI.01281-09]
  - 33 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]
  - 34 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]
  - 35 **Cao X**. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* 2020; **20**: 269-270 [PMID: 32273594 DOI: 10.1038/s41577-020-0308-3]
  - 36 **Velavan TP**, Meyer CG. Mild versus severe COVID-19: Laboratory markers. *Int J Infect Dis* 2020; **95**: 304-307 [PMID: 32344011 DOI: 10.1016/j.ijid.2020.04.061]
  - 37 **Ruan Q**, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; **46**: 846-848 [PMID: 32125452 DOI: 10.1007/s00134-020-05991-x]
  - 38 **He X**, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020; **26**: 672-675 [PMID: 32296168 DOI: 10.1038/s41591-020-0869-5]
  - 39 **Wiersinga WJ**, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* 2020; **324**: 782-793 [PMID: 32648899 DOI: 10.1001/jama.2020.12839]
  - 40 **Wang Y**, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**: 1569-1578 [PMID: 32423584 DOI: 10.1016/S0140-6736(20)31022-9]
  - 41 **Cai Q**, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering(Beijing)* 2020 [PMID: 32346491 DOI: 10.1016/j.eng.2020.03.007]
  - 42 **Cortegiani A**, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care* 2020; **57**: 279-283 [PMID: 32173110 DOI: 10.1016/j.jcrc.2020.03.005]
  - 43 **Chowdhury MS**, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. *Acad Emerg Med* 2020; **27**: 493-504 [PMID: 32359203 DOI: 10.1111/acem.14005]
  - 44 **Cao B**, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382**: 1787-1799 [PMID: 32187464 DOI: 10.1056/NEJMoa2001282]
  - 45 **Xu X**, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci USA* 2020; **117**: 10970-10975 [PMID: 32350134 DOI: 10.1073/pnas.2005615117]
  - 46 **RECOVERY Collaborative Group**. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D,

- Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* 2020 [PMID: [32678530](#) DOI: [10.1056/NEJMoa2021436](#)]
- 47 **Tomazini BM**, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA* 2020; **324**: 1307-1316 [PMID: [32876695](#) DOI: [10.1001/jama.2020.17021](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

